In this installment of HBW Insight’s “Inside Regulatory Affairs” series, Bayer Consumer Health’s global regulatory director, Jenny Holmes, describes how the job has changed in recent years to assume an enabling role for innovation.

In this installment of HBW Insight’s “Inside Regulatory Affairs” series, Meredith Spencer and Gary Peiffer, regulatory leaders at e.l.f. Beauty, discuss the accelerated pace of legislative and regulatory change around the world, increased focus on chemicals’ environmental as well as human health impacts, and the importance of driving a collaborative, “problem solver” mentality throughout organizations.

This HBW Insight series profiles regulatory affairs specialists working in or supporting the consumer health and beauty product industries. In this installment, we speak to AHPA's director of regulatory affairs, Robert Marriott.

In this installment of HBW Insight’s “Inside Regulatory Affairs” series, we hear from Sharee Crumbey and Monica Sharda, regulatory affairs specialists at The Honest Company, about the mounting challenges and rewards of the job.

Pink Sheet infographic shows how a large majority of novel drugs make it past the US FDA before receiving approval in the European Union. Lag times ranged from almost five years to less than two weeks.

Scrip analyzed data on top-selling drugs to see how long it takes to surpass $1bn in revenues and grow into $5bn and even $10bn brands.